デフォルト表紙
市場調査レポート
商品コード
1656901

プレフィルドシリンジの世界市場:洞察、競合情勢、市場予測:2032年

Prefilled Syringes - Market Insights, Competitive Landscape, and Market Forecast - 2032


出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2~10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
プレフィルドシリンジの世界市場:洞察、競合情勢、市場予測:2032年
出版日: 2025年01月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

プレフィルドシリンジの市場規模は、2024年に124億9,079万米ドルとなりました。同市場は、2025年から2032年までの予測期間中に10.73%のCAGRで拡大し、2032年には279億9,335万米ドルに達すると予測されています。世界のプレフィルドシリンジ市場は、慢性疾患の増加、生物製剤とバイオシミラーの使用増加、自己投与の採用により成長しています。糖尿病や関節リウマチのような慢性疾患は継続的な注射治療を必要とし、プレフィルドシリンジは患者に安全で便利な治療管理方法を提供します。がんや自己免疫疾患のような複雑な疾患に対する生物製剤やバイオシミラーの使用は、使いやすい注射システムの需要をさらに押し上げています。さらに、自宅での自己投与へのシフトが利便性を高め、プレフィルドシリンジの需要全体を押し上げています。これらの要因を総合すると、2025年から2032年までの予測期間中、プレフィルドシリンジは力強い成長軌道を描くことになります。

世界心臓機関(WHO)が提供した最近のデータ(2023年)によると、世界で約5億2,800万人が変形性関節症を患っています。

さらに、Institute for Health Metrics and Evaluationが提供した最近のデータ(2023年)によると、2050年までに約10億人が変形性関節症に罹患すると予測されており、最もよく罹患する部位は膝と腰です。具体的には、変形性膝関節症は74.9%、変形性手関節症は48.6%、変形性股関節症は78.6%、肘や肩などその他の部位の変形性関節症は95.1%増加すると予測されています。

変形性関節症の患者は、痛みの緩和や関節の可動性のためにヒアルロン酸やコルチコステロイドの注射を必要とすることが多いです。プレフィルドシリンジは、これらの治療を臨床や家庭で行うための便利で無菌の方法を提供し、世界のプレフィルドシリンジ市場を後押ししています。例えば、Sanofiの子会社であるGenzyme Corporationが製造するSynvisc-One(R)は、プレフィルドシリンジで、膝関節の潤滑とクッションを助け、変形性関節症の痛みを最長6ヶ月間緩和します。

さらに、世界保健機関(WHO)の最近のデータ(2023年)によると、世界で180万人以上が多発性硬化症に罹患していると報告されています。多発性硬化症は、免疫系が誤って脳や脊髄を攻撃するため、認知、感情、運動、感覚、視覚能力など、さまざまな機能に影響を及ぼします。プレフィルドシリンジは、すぐに使用でき、正確で使いやすい送達システムを提供することで、投与を簡素化し、投薬ミスを減らし、患者の治療レジメンへのアドヒアランスを高めるため、この症状を管理する上で極めて重要でした。例えば、AVONEXは再発性多発性硬化症の週1回の治療薬で、30mcgの筋肉内プレフィルドセルフシリンジとして提供されます。

さらに、モノクローナル抗体、成長因子、ワクチンなどの生物製剤は、がんや自己免疫疾患のような慢性疾患の治療に不可欠です。注射によって投与されるプレフィルドシリンジは、便利で正確な送達方法を提供します。さらに、生物製剤のバイオシミラー・ジェネリックの台頭がプレフィルドシリンジの需要をさらに押し上げ、より安価な治療選択肢を提供しています。

当レポートでは、世界のプレフィルドシリンジ市場について調査し、市場の概要とともに、製品タイプ別、素材別、タイプ別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プレフィルドシリンジ市場レポートのイントロダクション

第2章 プレフィルドシリンジ市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第5章 プレフィルドシリンジ市場の主な要因分析

  • プレフィルドシリンジ市場の促進要因
  • プレフィルドシリンジ市場の抑制要因と課題
  • プレフィルドシリンジ市場の機会

第6章 プレフィルドシリンジ市場におけるポーターのファイブフォース分析

第7章 プレフィルドシリンジ市場の評価

  • 製品タイプ別
    • ステークニードルシステム
    • ルアーコーンシステム
    • ルアーロックシステム
  • 素材別
    • ガラス
    • プラスチック
  • タイプ別
    • 針付き
    • 針なし
  • 流通チャネル別
    • 病院および薬局
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 プレフィルドシリンジ市場の企業と製品プロファイル

  • BD
  • Nipro Corporation
  • Taisei Kako Co., Ltd.
  • Terumo Corporation
  • SCHOTT Pharma AG & Co. KGaA
  • Gerresheimer AG
  • Johnson and Johnson Services, Inc.
  • Dali Medical Devices
  • Stevanato Groupand
  • Credence MedSystems, Inc.
  • Baxter
  • MAEDA INDUSTRY Co., Ltd.
  • MedXL, Inc.
  • Sanofi
  • Sandoz AG
  • Pfizer Inc.
  • B. Braun Melsungen AG
  • Novartis AG
  • Fresenius SE & Co. KGaA
  • Cardinal Health

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Prefilled Syringes Market in Global (2022-2032)
  • Table 3: Prefilled Syringes Market in Global by Product Type (2022-2032)
  • Table 4: Prefilled Syringes Market in Global by Material (2022-2032)
  • Table 5: Prefilled Syringes Market in Global by Type (2022-2032)
  • Table 6: Prefilled Syringes Market in Global by Distribution Channel (2022-2032)
  • Table 7: Prefilled Syringes Market in Global by Geography (2022-2032)
  • Table 8: Prefilled Syringes Market in North America (2022-2032)
  • Table 9: Prefilled Syringes Market in the United States (2022-2032)
  • Table 10: Prefilled Syringes Market in Canada (2022-2032)
  • Table 11: Prefilled Syringes Market in Mexico (2022-2032)
  • Table 12: Prefilled Syringes Market in Europe (2022-2032)
  • Table 13: Prefilled Syringes Market in France (2022-2032)
  • Table 14: Prefilled Syringes Market in Germany (2022-2032)
  • Table 15: Prefilled Syringes Market in the United Kingdom (2022-2032)
  • Table 16: Prefilled Syringes Market in Italy (2022-2032)
  • Table 17: Prefilled Syringes Market in Spain (2022-2032)
  • Table 18: Prefilled Syringes Market in the Rest of Europe (2022-2032)
  • Table 19: Prefilled Syringes Market in Asia-Pacific (2022-2032)
  • Table 20: Prefilled Syringes Market in China (2022-2032)
  • Table 21: Prefilled Syringes Market in Japan (2022-2032)
  • Table 22: Prefilled Syringes Market in India (2022-2032)
  • Table 23: Prefilled Syringes Market in Australia (2022-2032)
  • Table 24: Prefilled Syringes Market in South Korea (2022-2032)
  • Table 25: Prefilled Syringes Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: Prefilled Syringes Market in the Rest of the World (2022-2032)
  • Table 27: Prefilled Syringes Market in the Middle East (2022-2032)
  • Table 28: Prefilled Syringes Market in Africa (2022-2032)
  • Table 29: Prefilled Syringes Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Prefilled Syringes Market in Global (2022-2032)
  • Figure 3: Prefilled Syringes Market in Global by Product Type (2022-2032)
  • Figure 4: Prefilled Syringes Market in Global by Material (2022-2032)
  • Figure 5: Prefilled Syringes Market in Global by Type ((2022-2032)
  • Figure 6: Prefilled Syringes Market in Global by Distribution Channel (2022-2032)
  • Figure 7: Prefilled Syringes Market in Global by Geography (2022-2032)
  • Figure 8: Prefilled Syringes Market in North America (2022-2032)
  • Figure 9: Prefilled Syringes Market in the United States (2022-2032)
  • Figure 10: Prefilled Syringes Market in Canada (2022-2032)
  • Figure 11: Prefilled Syringes Market in Mexico (2022-2032)
  • Figure 12: Prefilled Syringes Market in Europe (2022-2032)
  • Figure 13: Prefilled Syringes Market in France (2022-2032)
  • Figure 14: Prefilled Syringes Market in Germany (2022-2032)
  • Figure 15: Prefilled Syringes Market in the United Kingdom (2022-2032)
  • Figure 16: Prefilled Syringes Market in Italy (2022-2032)
  • Figure 17: Prefilled Syringes Market in Spain (2022-2032)
  • Figure 18: Prefilled Syringes Market in the Rest of Europe (2022-2032)
  • Figure 19: Prefilled Syringes Market in Asia-Pacific (2022-2032)
  • Figure 20: Prefilled Syringes Market in China (2022-2032)
  • Figure 21: Prefilled Syringes Market in Japan (2022-2032)
  • Figure 22: Prefilled Syringes Market in India (2022-2032)
  • Figure 23: Prefilled Syringes Market in Australia (2022-2032)
  • Figure 24: Prefilled Syringes Market in South Korea (2022-2032)
  • Figure 25: Prefilled Syringes Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: Prefilled Syringes Market in the Rest of the World (2022-2032)
  • Figure 27: Prefilled Syringes Market in the Middle East (2022-2032)
  • Figure 28: Prefilled Syringes Market in Africa (2022-2032)
  • Figure 29: Prefilled Syringes Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Market Opportunities
  • Figure 33: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0107

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic diseases, increase impact of biologics and biosimilar on prefilled syringes, increase adoption of self-administration across the globe.

The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032. The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.

Prefilled Syringes Market Dynamics:

According to the recent data provided by the World Heart Organization (2023), about 528 million people globally were living with osteoarthritis.

Additionally, according to the recent data provided by the Institute for Health Metrics and Evaluation (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, osteoarthritis of the knee is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%.

Patients with osteoarthritis often need hyaluronic acid or corticosteroid injections for pain relief and joint mobility. Prefilled syringes provide a convenient and sterile method for administering these treatments in clinical and home settings, thus boosting the global prefilled syringe market. For example, Synvisc-One(R) manufactured by Genzyme Corporation, which is a subsidiary of Sanofi is a prefilled syringe that helps lubricate and cushion the knee joint, offering relief from osteoarthritis pain for up to six months.

Additionally, as per recent data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide were affected by multiple sclerosis. Multiple sclerosis impacted various functions, including cognitive, emotional, motor, sensory, and visual abilities, as the immune system mistakenly attacked the brain and spinal cord. Prefilled syringes were crucial for managing the condition, as they simplified dosing, reduced medication errors, and enhanced patient adherence to treatment regimens by offering a ready-to-use, accurate, and user-friendly delivery system. For instance, AVONEX is a once-weekly treatment for relapsing multiple sclerosis, provided as a 30 mcg intramuscular prefilled self-syringe.

Moreover, Biologics, including monoclonal antibodies, growth factors, and vaccines, are crucial for treating chronic conditions like cancer and autoimmune diseases. Administered via injection, prefilled syringes offer a convenient and accurate delivery method. Additionally, the rise of biosimilar generic versions of biologics has further propelled the demand for prefilled syringes, providing a more affordable treatment option.

For instance, in July 2024, Sandoz Group AG, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) approved its biosimilar Pyzchiva(R)* (ustekinumab-ttwe) in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection, as well as a 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion.

Thus, the factors mentioned above are expected to boost the overall market of prefilled syringes across the globe during the forecast period from 2025 to 2032.

However, increasing product recalls and failures due to safety issues and the availability of alternative products may hinder the future market of prefilled syringes across the globe during the forecasted period.

Prefilled Syringes Market Segment Analysis:

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The staked needle system category in the prefilled syringes market is estimated to dominate the market with a market share of 68.37% in 2024. The adoption of staked needle systems is significantly boosting the overall market of prefilled syringes by addressing key challenges in drug delivery and enhancing the usability, safety, and efficiency of injectable therapies. A staked needle system integrates the needle directly into the syringe barrel, eliminating the need for additional assembly, such as attaching a separate needle. This design simplifies the injection process, reduces preparation time, and minimizes the risk of needle-related complications, such as detachment or improper attachment, making it highly preferred in both clinical and self-administration settings.

One of the major drivers of the staked needle system's impact is its contribution to patient safety. The fixed-needle design reduces the risk of needle-stick injuries, which is a critical concern for healthcare professionals, especially in high-pressure environments like hospitals and emergency care. Additionally, the reduced dead space in staked needle systems ensures precise dosing and minimizes medication waste, which is particularly advantageous for high-cost biologics, vaccines, and specialty drugs. This attribute makes staked needle systems an ideal choice for administering small-volume, high-potency medications, aligning with the growing demand for precision medicine. The integration of staked needle systems into advanced prefilled syringes, such as autoinjectors and pen injectors, further boosts their appeal in the rapidly growing self-injection device market.

Pharmaceutical companies are increasingly adopting staked needle systems for their prefilled syringes due to their compatibility with a wide range of drugs, including biologics and biosimilars, which are gaining traction globally. The design ensures the sterility and integrity of the drug product, reducing the likelihood of contamination or degradation. Furthermore, staked needle systems are well-suited for high-speed, automated manufacturing processes, enabling efficient large-scale production while maintaining consistent quality, which aligns with the rising demand for prefilled syringes worldwide.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of prefilled syringes across the globe.

North America is expected to dominate the overall prefilled syringes market:

Among all regions, North America is estimated to hold the largest share of 34% in the global prefilled syringes market in 2024, growing at a CAGR of 11.02% during the forecast period from 2025 to 2032. This can be attributed to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in 2023, it was estimated that around 53.2 million people (21.2%), had been diagnosed with arthritis and rheumatoid arthritis in the United States, between 2019 to 2021.

Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, it was stated that around 38.4 million, accounting for 11.6% of the US population was suffering from diabetes, in 2021. Chronic diseases like diabetes and rheumatoid arthritis require continuous treatment over the long term. Patients need regular injections to manage their conditions, often for the rest of their lives. Prefilled syringes make these daily treatments easier, and more accurate, and allow easy self-administration of medications at home.

Furthermore, the well-established patient care system along with high awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the United States prefilled syringes market growth.

Moreover, the increasing use of prefilled syringes highlights the rapid adoption of technologically advanced solutions, which is expected to drive market growth. For instance, in March 2024, Mallinckrodt plc. announced that the U.S. FDA approved the Acthar(R) Gel (repository corticotropin injection) Single-Dose SelfJect(TM) Injector, a new delivery device for Acthar Gel for patients with chronic and acute inflammatory and autoimmune conditions. The SelfJect was designed to allow patients greater control over their medication administration.

Thus, the above-mentioned factors are expected to escalate the market of prefilled syringes in the region.

Prefilled Syringes Market Key Players:

Some of the key market players operating in the Prefilled Syringes market include BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.

Recent Developmental Activities in the Prefilled Syringes Market:

  • In March 2024, SCHOTT Pharma expanded in the U.S. with a new prefillable syringe manufacturing facility in Wilson, North Carolina with a $371 million investment.
  • In May 2024, InvAscent, through India Life Sciences IV (ILSF IV), partnered with Morgan Stanley Private Equity Asia to invest INR 10,000 million in Maiva Pharma, recognized as India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds raised were intended to enhance vial, lyophilization, and suspension capacity, as well as to introduce new manufacturing capabilities, including prefilled syringes, cartridges, and bags.

Key Takeaways From the Prefilled Syringes Market Report Study

  • Market size analysis for current prefilled syringes size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the prefilled syringes market.
  • Various opportunities available for the other competitors in the prefilled syringes market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current prefilled syringes market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for prefilled syringes market growth in the coming future?

Target Audience Who Can be Benefited From This Prefilled Syringes Market Report Study

  • Prefilled syringes product providers
  • Research organizations and consulting companies
  • Prefilled syringes-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in prefilled syringes
  • Various end-users who want to know more about the prefilled syringes market and the latest technological developments in the prefilled syringes market.

Frequently Asked Questions for the Prefilled Syringes Market:

1. What are prefilled syringes?

  • Prefilled syringes are medical devices that deliver medication in precise, pre-measured doses, ready for immediate use. These syringes filled with liquid medication have a securely attached needle, ensuring safety and eliminating the need for preparation.

2. What is the market for prefilled syringes?

  • The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032.

3. What are the drivers for the global prefilled syringes market?

  • The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global prefilled syringes market?

  • Some of the key market players operating in the prefilled syringes are BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.

5. Which region has the highest share in the global prefilled syringes market?

  • North America region is anticipated to dominate the overall prefilled syringes market due to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.

Table of Contents

1. Prefilled Syringes Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Prefilled Syringes Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Prefilled Syringes Market Key Factors Analysis

  • 5.1. Prefilled Syringes Market Drivers
    • 5.1.1. The increasing prevalence of chronic diseases
    • 5.1.2. Increase impact of biologics and biosimilar on prefilled syringes
    • 5.1.3. Increase adoption of self-administration across the globe
  • 5.2. Prefilled Syringes Market Restraints and Challenges
    • 5.2.1. Increasing product recalls and failures due to safety issues
    • 5.2.2. Availability of alternative products
  • 5.3. Prefilled Syringes Market Opportunities
    • 5.3.1. Increased funding and investment for more extensive research and development activities

6. Prefilled Syringes Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Prefilled Syringes Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Staked Needle System
    • 7.1.2. Luer Cone System
    • 7.1.3. Luer Lock System
  • 7.2. By Material
    • 7.2.1. Glass
    • 7.2.2. Plastic
  • 7.3. By Type
    • 7.3.1. With Needle
    • 7.3.2. Without Needle
  • 7.4. By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Online Pharmacies
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.1.2. Canada Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.1.3. Mexico Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.2. Germany Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.3. United Kingdom Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.4. Italy Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.5. Spain Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.6. Rest of Europe Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.2. Japan Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.3. India Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.4. Australia Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.5. South Korea Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.4.2. Africa Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.4.3. South America Prefilled Syringes Market Size in USD Million (2022-2032)

8. Prefilled Syringes Market Company and Product Profiles

  • 8.1. BD
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Nipro Corporation
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Taisei Kako Co., Ltd.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Terumo Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. SCHOTT Pharma AG & Co. KGaA
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Gerresheimer AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Johnson and Johnson Services, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Dali Medical Devices
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Stevanato Groupand
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Credence MedSystems, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Baxter
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. MAEDA INDUSTRY Co., Ltd.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. MedXL, Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Sanofi
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Sandoz AG
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Pfizer Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. B. Braun Melsungen AG
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Novartis AG
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Fresenius SE & Co. KGaA
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cardinal Health
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us